検索結果

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica

nical Trial Summaries ※Listed in order of date of first publication Medical Condition Phase Project Code Country Recruitment Status Access to Trial ID Allergic Conjunctivitis 2 SJP-0049 Japan Active, ...

nnounces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 was granted by the Ministry of Health, Labor and Welfare (HMLW) on June 19, 2024, as a...

tarted Phase III clinical trials in Japan for an in-house developed compound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs w...

tarted Phase III clinical trials in Japan for an in-house developed compound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs w...

ka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President...